Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue 6, 1997, Pages 757-762

  Vila, Jordi ^a   Ruiz, Joaquim ^a   Goñi, Pilar ^a   De Anta, Teresa Jimenez ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE;

ACINETOBACTER; AMINO ACID SEQUENCE; ANTI-INFECTIVE AGENTS; BASE SEQUENCE; CIPROFLOXACIN; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MICROBIAL; GENES, BACTERIAL; MOLECULAR SEQUENCE DATA; POINT MUTATION; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0030851997     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.6.757     Document Type: Article

References (37)

1. Bergogne-Bérézin, E. & Towner, K. J. (1996). Acinetobacter spp. as nosocomial pathogens: microbiological, clinical and epidemiological features. Clinical Microbiology Reviews 9, 148-65.
2. Urban, C., Go, E., Mariano, N., Berger, B. J., Avraham, I., Rubin, D. et al. (1993). Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. Journal of Infectious Diseases 167, 448-51.
3. Wood, C. A. & Reboli, A. C. (1993). Infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. Journal of Infectious Diseases 168, 1602-3.
4. Go, E. S., Urban, C., Burns, J., Kreiswirth, B., Eisner, W., Mariano, N. et al. (1994). Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344, 1329-32.
5. Traub, W. H. & Spohr, M. (1989). Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6). Antimicrobial Agents and Chemotherapy 33, 1617-9.
6. Acar, J. F., O'Brien, T. F., Goldstein, F. W. & Jones, R. N. (1993). The epidemiology of bacterial resistance to quinolones. Drugs 45, Suppl. 3, 24-8.
7. Vila, J., Marcos, M. A., Marco, F., Abdalla, S., Vergara, Y., Reig, R. et al. (1993). In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 37, 138-41.
8. Yoshida, H., Kojima, T., Yamagishi, J. & Nakamura, S. (1988). Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Molecular and General Genetics 211, 1-7.
9. Yoshida, H., Bogaki, M., Nakamura, M. & Nakamura, S. (1990). Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrobial Agents and Chemotherapy 34, 1271-2.
10. Oram, M. & Fisher, L. M. (1991). 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrobial Agents and Chemotherapy 35, 387-9.
11. Cambau, E., Bordon, F., Collatz, E. & Gutmann, L. (1993). Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid. Antimicrobial Agents and Chemotherapy 37, 1247-52.
12. Heisig, P., Schedletzky, H. & Falkenstein-Paul, H. (1993). Mutations in pyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrobial Agents and Chemotherapy 37, 696-701.
13. Vila, J., Ruiz, J., Marco, F., Barceló, A., Goñi, P., Giralt, E. et al. (1994). Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrobial Agents and Chemotherapy 38, 2477-9.
14. Hirai, K., Aoyama, H., Irikura, T., Iyobe, S. & Mitsuhashi, S. (1986). Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrobial Agents and Chemotherapy 29, 535-8.
15. Hirai, K., Aoyama, H., Suzue, S., Irikura, T., Iyobe, S. & Mitsuhashi, S. (1986). Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrobial Agents and Chemotherapy 30, 248-53.
16. Cohen, S. P., Hooper, D. C., Wolfson, J. S., Souza, K. S., McMurry, L. M. & Levy, S. B. (1988). Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrobial Agents and Chemotherapy 32, 1187-91.
17. Cohen, S. P., McMurry, L. M., Hooper, D. C., Wolfson, J. S. & Levy, S. B. (1989). Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrobial Agents and Chemotherapy 33, 1318-25.
18. Hooper, D. C., Wolfson, J. S., Souza, K. S., Ng, E. Y., McHugh, G. L. & Swartz, M. N. (1989). Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation. Antimicrobial Agents and Chemotherapy 33, 283-90.
19. Hooper, D. C., Wolfson, J. S., Bozza, M. A. & Ng, E. Y. (1992). Genetics and regulation of outer membrane protein expression by quinolone resistance loci nfxB, nfxC, and cfxB. Antimicrobial Agents and Chemotherapy 36, 1151-4.
20. Kato, J., Nishimura, Y., Imamura, R., Niki, H., Higara, S. & Suzuki, H. (1990). New topoisomerase essential for chromosome segregation in E. coli. Cell 63, 393-404.
21. Peng, H. & Marians, K. J. (1993). Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions. Journal of Biological Chemistry 268, 24481-90.
22. Khodursky, A. B., Zechiedrich, E. & Cozzarelli, N. R. (1995). Topoisomerase IV is a target of quinolones in Escherichia coll. Proceedings of the National Academy of Sciences of the United States of America 92, 11801-5.
23. Vila, J., Ruiz, J., Goñi, P. & Jimenez de Anta, M. T. (1996). Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coll. Antimicrobial Agents and Chemotherapy 40, 491-3.
24. Heisig, P. (1996). Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrobial Agents and Chemotherapy 40, 879-85.
25. Vila, J., Ruiz, J., Goñi, P., Marcos, A. & Jimenez de Anta, T. (1995). Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 39, 1201-3.
26. Bouvet, P. J. M. & Grimont, P. A. D. (1986). Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov., and Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., and Acinetobacter junii sp. nov. and emended descriptions of Acinetobacter calcoaceticus and Acinetobacter Iwoffii. International Journal of Systematic Bacteriology 36, 228-40.
27. Vila, J., Marcos, M. A. & Jimenez de Anta, M. T. (1996). A comparative study of different PCR-based DNA fingerprinting techniques for typing of the Acinetobacter calcoaceticus-A. baumannii complex. Journal of Medical Microbiology 44, 482-9.
28. Marcos, M. A., Jimenez de Anta, M. T. & Vila, J. (1995). Correlation of six methods for typing nosocomial isolates of Acinetobacter baumannii. Journal of Medical Microbiology 42, 328-35.
29. National Committee for Clinical Laboratory Standards. (1990). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Second Edition; Approved Standard M7-A2. NCCLS, Villanova, PA.
30. Soussy, C. J., Wolfson, J. S., Ng, E. Y. & Hooper, D. C. (1993). Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus. Antimicrobial Agents and Chemotherapy 37, 2588-92.
31. Ferrero, L., Cameron, B., Manse, B., Lagneaux, D., Crouzet, J., Famechon, A. et al. (1994). Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Molecular Microbiology 13, 641-53.
32. Ferrero, L., Cameron, B. & Crouzet, J. (1995). Analysis of gyrA and gr/A mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 39, 1554-8.
33. Belland, R. J., Morrison, S. G., Ison, C. & Huang, W. M. (1994). Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Molecular Microbiology 14, 371-80.
34. Sato, K. & Nakae, T. (1991). Outer membrane permeability of Acinetobacter calcoaceticus and its implication in antibiotic resistance. Journal of Antimicrobial Chemotherapy 28, 35-45.
35. Angus, B. L., Carey, A. M., Caron, D. A., Kropinski, A. M. B. & Hancock, R. E. W. (1982). Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild-type with an antibiotic-supersusceptible mutant. Antimicrobial Agents and Chemotherapy 21, 299-309.
36. Yoshimura, F. & Nikaido, H. (1982). Permeability of Pseudomonas aeruginosa outer membrane to hydrophilic solutes. Journal of Bacteriology 152, 636-42.
37. Li, X. Z., Livermore, D. M. & Nikaido, H. (1994). Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrobial Agents and Chemotherapy 38, 1732-41.